Deferiprone for thalassaemia.
| Publicado en: | Lancet Vol. 356; no. 9239; pp. 1444 - 1446 |
|---|---|
| Autores principales: | , |
| Formato: | commentary Journal Article |
| Publicado: |
Lancet
10/21/2000
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=133362372&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 133362372 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 01406736 LAN jtl: Lancet issn: 01406736 maglogo: N pubinfo: dt: 10/21/2000 vid: 356 iid: 9239 pid: 1297 pub: Lancet place: Philadelphia, Pennsylvania artinfo: ui: 133362372 133362372 NLM11052617 133362372 10.1016/s0140-6736(05)74089-7 NLM11052617 133362372 ppf: 1444 ppct: 2 formats: fmt: @attributes: type: P tig: atl: Deferiprone for thalassaemia. aug: au: Pippard, M J Weatherall, D J sug: subj: Chelating Agents Adverse Effects Pyridines Adverse Effects Thalassemia Drug Therapy Administration, Oral Chelating Agents Administration and Dosage Pyridines Administration and Dosage pubtype: Academic Journal doctype: commentary Journal Article ougenre: Unknown ab: language: English refInfo: holdings: @attributes: islocal: N |
|---|